<DOC>
	<DOC>NCT00441155</DOC>
	<brief_summary>To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST</brief_summary>
	<brief_title>Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criteria: Documented Complete Response, Partial Response, or Stable Disease at the time of entry to extension study and/or possible benefit from continuing treatment in the view of the investigator. Normal organ and marrow function as defined in core protocol (CAMN107A2103). Extension protocol written informed consent. Exclusion criteria: Inability to swallow the medication. Any unresolved adverse events related to participation in the core protocol (CAMN107A2103). A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits. Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Imatinib-Resistant Gastrointestinal Stromal Tumors</keyword>
	<keyword>GIST</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)</keyword>
</DOC>